Phase 3 Results Published for Enhanced Flu Vaccine for Seniors

CSL Seqirus announced the publication of pivotal Phase 3 study results in The Lancet Infectious Diseases for its MF59®-adjuvanted cell-based higher-dose quadrivalent influenza vaccine (aQIVc). This vaccine uniquely combines an adjuvant, cell-based manufacturing, and a higher dose to boost protection in older adults. The findings represent a significant advancement in influenza prevention for this vulnerable demographic.